Skip to content

Modelling Internal Hepatic Movement With an External Abdominal Marker

Modelling Internal Hepatic Movement With an External Abdominal Marker Block for Use With a Real Time Position Monitoring System for Respiratory Gating

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00299299
Enrollment
10
Registered
2006-03-06
Start date
2006-06-30
Completion date
Unknown
Last updated
2010-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Liver Metastases From Colorectal Cancer

Brief summary

This study tests the feasibility and reproducibility of patient-specific motion models. These will be used for quantification of safe margin reduction. Patient-specific motion models will be built by post-processing 4D MRI data with non-rigid registration. By comparing these models between visits, model reproducibility will be assessed, and the methodology refined.

Detailed description

The study will use a real time position management (RPM) system for respiratory gating. The RPM system senses the respiration motion of the patient by tracking a pair of reflective markers on a lightweight marker block constructed of a synthetic material. This block is placed on the patient's abdomen. During Radiotherapy, the beam is only switched on at pre-determined phases of respiration. The appropriate phase of respiration is determined by the RPM system. This implies a reliable correlation of external block motion to internal hepatic movement. This correlation is not a simple one, and requires modeling.

Interventions

None listed

Sponsors

Royal Marsden NHS Foundation Trust
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed adenocarcinoma compatible with primary disease in the colon or rectum * Aged 18 years or older * Unequivocal contrast-enhanced CT and/or MRI evidence of malignant single or multiple metastases in the liver, metastases at other sites will not be an exclusion criterion * WHO performance status 0-2 and life expectancy of at least 12 weeks * Informed written consent

Exclusion criteria

* Pregnancy or breast feeding * Evidence of ascites * Patients unable for whatever reason to lie flat * Patients unable to give fully informed consent * Age\< 18 years

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026